Rosuvastatin for the treatment of hypercholesterolemia

Pharmacotherapy

Volumn 25, Issue 7, 2005, Pages 990-1000

  Culhane, Nicole S ^a   Lettieri, Shana L ^a   Skae, Jeannine R ^a  

^a WILKES UNIVERSITY   (United States)

Author keywords

HMG CoA reductase inhibitor; Hypercholesterolemia; Hyperlipidemia; LDL; Low density lipoprotein cholesterol; Rosuvastatin calcium

Indexed keywords

ALUMINUM HYDROXIDE; AMIODARONE; ANTACID AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; CIMETIDINE; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; DICLOFENAC; DIGOXIN; ERYTHROMYCIN; ETHINYLESTRADIOL; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; ITRACONAZOLE; KETOCONAZOLE; MAGNESIUM HYDROXIDE; MEVINOLIN; NICOTINIC ACID; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; PRAVASTATIN; PROPRANOLOL; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; VERAPAMIL; WARFARIN;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BINDING AFFINITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG COST; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; FLATULENCE; HEADACHE; HEALTH EDUCATION; HEALTH PROGRAM; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; MYALGIA; MYOPATHY; NAUSEA; PAIN; PHARYNGITIS; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; SINUSITIS; XEROSTOMIA;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; FLUOROBENZENES; HUMANS; HYPERCHOLESTEROLEMIA; PYRIMIDINES; SULFONAMIDES;

EID: 21444433649     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.7.990     Document Type: Review

References (65)

1. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986;256:2835-8.
2. Stamler J, Wentworth D, Neaton JD, for the MRFIT Research Group. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous or graded? JAMA 1986;256:2823-8.
3. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the multiple risk factors intervention trial. Arch Intern Med 1992;152:1490-500.
4. Pedersen TR, Kjekshus J, Berg K, et al, for the Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
5. Lee CH, deFeyter P, Serruys PW, et al. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). Heart 2004;90:1156-61.
6. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
7. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels; results of AFCAPS/TexCAPS. JAMA 1998;279:1616-22.
8. Collins R, Armitage J, Parish S, Sleight P, Peto R, for the Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
9. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average and lower-than-average cholesterol concentrations, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-58.
10. Shepard J, Cobbe SM, Ford I, et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
11. Pearson TA, Laurora I, Chu H, Karonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
12. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary heart disease. Am J Cardiol 1999;83:1303-7.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285(19):2486-97.
14. Grundy SM, Cleeman JI, Baiery Merz N, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004;110:227-39.
15. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndrome. N Engl J Med 2004;350:1495-504.
16. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of A to Z trial. JAMA 2004;292:1307-16.
17. AstraZeneca Pharmaceuticals LP. Crestor (rosuvastatin calcium) prescribing information. Wilmington, DE; August 2003.
18. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 2003;4:9-14.
19. McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol 2003;26(suppl III):III32-8.
20. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87(suppl):28B-32.
21. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42: 963-70.
22. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472-7.
23. Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003;25:2553-63.
24. Prueksaritanont T, Zhao JJ, Bennett MA, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-51.
25. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505-12.
26. Prueksaritanont T, Tang C, Qui Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280-7.
27. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822-35.
28. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42:1116-21.
29. Kiman K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004;44:1083-105.
30. Schuster H, Fox J. Investigating cardiovascular risk reduction: the rosuvastatin GALAXY programme. Expert Opin Pharmacother 2004;5:1187-200.
31. Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003;58:669-75.
32. Olsson AG, Istad H, Luurila O, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J 2002;144:1044-51.
33. Davidson M, Ma P, Stein EA, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89:268-75.
34. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003;91:33-41.
35. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein compared with pravastatin and simvastatin in hypercholesterolemic patients: a randomized, double-blind study. J Cardiovasc Risk 2001;8:383-90.
36. Brown VW, Bays HE, Hassman DR, et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002;144:1036-43.
37. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR). Am J Cardiol 2003;93:152-60.
38. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG, Cressman MD. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003;91:1304-10.
39. Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effects of niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther 1996;1:195-202.
40. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of efficacy of Niaspan trial. Arch Intern Med 2002;162:1568-76.
41. Schuster H, Barter PJ, Slender S, et al. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J 2004;147:705-12.
42. Pasternak RC, Smith SC, Baiery-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Am J Coll Cardiol 2002;40:567-72.
43. Shepard J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. Am J Cardiol 2004;94:882-8.
44. Wooltorton E. Rosuvastatin (Crestor) and rhabdomyolysis [alert]. Can Med Assoc J 2004;171:129.
45. U.S. Food and Drug Administration. FDA public health advisory for Crestor (rosuvastatin), June 9, 2004. Available from www.fda.gov/cder/drug/advisory/ crestor.htm. Accessed June 12, 2004.
46. Sidaway JE, Davidson RG, McTaggart F, et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004;15:2258-65.
47. Brewer BH. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003;92:23K-9.
48. Vidt G, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004;102:52-60.
49. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51-6.
50. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003;73:322-9.
51. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW. Lack of efficacy of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003;55:94-9.
52. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527-31.
53. Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 2002;42:1352-7.
54. Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459-71.
55. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-77.
56. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75(5):455-63.
57. Barry M. Rosuvastatin-warfarin drug interaction [comment]. Lancet 2004;363:328.
58. Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW. The effect on estrogen and progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol 2004;57(3):279-86.
59. Hansten PD, Horn JR. Drug interactions analysis and management. St. Louis: Wolters Kluwer Health, Inc., 2004.
60. Anonymous. Physicians' desk reference. Montvale, NJ: Thomson Healthcare, 2004.
61. Andrus MR. Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmacotherapy 2004;24:285-90.
62. Klasko RK, ed. Drugdex system. Greenwood Village, CO: Thomson Micromedex; edition expires December 2004.
63. U.S. Food and Drug Administration. Advisory committee briefing document: pharmacology/toxicology. Available from http://www.fda.gov/ohrms/dockets/ac/03/ briefing/3968B1_02_F -FDA-pharmTox%20Review.pdf. Accessed March 2004.
64. Theheart.org. Doctors warned on starting doses of rosuvastatin. Available from www.theheart.org/viewarticle.do? primarykey=137293&from=/searchlayout. do. Accessed December 20, 2004.
65. Cardinale V, ed. Drug topics red book. Montvale, NJ: Medical Economics Company, 2004.